Multiple myeloma: IgG (50 %), IgA (20 %), IgD (few), free light chains (17 %) Serum light chain quantitation Venous blood sample. Provides a rapid, accurate, quantitative measurement of λ and κ ...

4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

A multiple myeloma diagnosis is a life event that can be overwhelming. Get trusted information for every step of your journey. Multiple myeloma can be tricky. That’s because it sometimes has no ...

Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...

Multiple myeloma is a type of cancer where plasma cells in bone marrow replicate out of control. Doctors use the acronym CRAB to diagnose myeloma by identifying four symptoms. The National Cancer ...

It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

We do not know what causes MGUS. There may be a link to autoimmune diseases, genetics, or environmental factors. Like multiple myeloma, MGUS starts in a type of white blood cell called plasma cells.

A stem cell transplant can be a good treatment for multiple myeloma. A successful transplant gives someone with multiple myeloma new, healthy bone marrow. It replaces the bone marrow harmed by myeloma ...

Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL ... first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible.

Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...